Hyperthermia therapy in China
Heat is one of the oldest ideas in medicine and one of the best-studied adjuncts in oncology. It is also the easiest thing in a longevity brochure to describe in a way that sounds like a sauna with a physician attached. Here is what the temperature is actually doing, where the randomised evidence is, and where it runs out.
The short answer
Hyperthermia therapy is the controlled heating of tissue to a measured temperature for a measured time — usually somewhere between 39°C and 43°C — under monitoring. In the Boao Lecheng pilot zone in Hainan it is delivered as whole-body immune hyperthermia in the hospital’s day-treatment unit, and it sits on the non-cell side of the programme menu alongside therapeutic plasma exchange, 1+X functional infusion medicine, the mitochondrial and NAD+ course and hyperbaric oxygen. Session-based, no cleanroom, no batch, no two-week manufacturing run.
The evidence splits cleanly in two, and almost every piece of marketing you will read blurs the seam. Regional hyperthermia added to radiotherapy or chemotherapy, in named cancers, inside an oncology plan has randomised trials behind it going back to the 1990s, and they are good trials. Fever-range whole-body hyperthermia in a healthy person, for longevity has a plausible mechanism, a scatter of small studies in depression and pain, and no trial that has ever measured whether it makes anyone live longer. Both sentences are true. Only one of them is about the thing a well guest would be booking.
Three different things share the name
Ask a European radiation oncologist, a Chinese oncology ward and a longevity spa what hyperthermia is and you will get three answers, all correct.
| Form | Target | Where it lives |
|---|---|---|
| Local & regional capacitive or microwave applicators over one site or region | 40–43°C in the heated volume | Oncology, alongside radiotherapy or chemotherapy. This is where the randomised evidence is. |
| Fever-range whole-body infrared or water-filtered infrared cabin, whole core | 38.5–40°C core | Immune and inflammatory indications; the form used in wellness and retreat settings, including here. |
| Extreme whole-body | 41.8–42°C core | Intensive-care-grade, sedation and invasive monitoring. Not a wellness procedure in any sense, and not what is offered on a retreat. |
A sauna is none of the three. It heats the air; your core rises by an amount nobody measures. In clinical hyperthermia the dose is the temperature and the duration, and if neither is measured there is no dose — only a warm room and a receipt.
What the heat is actually doing
Four mechanisms are reasonably well established, and they explain why hyperthermia is an adjunct rather than a treatment in its own right.
Where hyperthermia is established medicine
These are the trials. They are cited here so you can read them yourself, not as a promise of outcome, and every one of them is adjunct therapy inside a cancer treatment plan run by an oncologist.
Two cautions that the brochures omit. First, the delivered benefit depends almost entirely on thermometry and quality assurance — the European Society for Hyperthermic Oncology publishes quality guidelines precisely because a machine that cannot verify the temperature it reached has not delivered the dose the trials tested. Second, none of these results is a result about heat alone. Remove the radiotherapy or the chemotherapy and there is no trial left.
Where the longevity claim comes from
Honestly? From three places, none of which is a longevity trial.
Hormesis and the heat-shock response. A sublethal stress provokes a protective response: chaperone proteins that refold damaged proteins, and a cascade associated with improved proteostasis. In invertebrates and cell systems, heat-shock preconditioning genuinely extends survival under later stress. Extrapolating from a nematode to a sixty-year-old in a cabin is an argument, not a finding.
The sauna epidemiology. The Finnish KIHD cohort (Laukkanen and colleagues, JAMA Internal Medicine, 2015) followed 2,315 middle-aged men and found frequent sauna bathing associated with lower cardiovascular and all-cause mortality. It is a well-conducted observational study, it is about saunas rather than clinical hyperthermia, and observational associations of this kind are the classic setting for confounding by health status: the men well enough to sauna four times a week are not a random sample.
Small clinical studies outside oncology. A single-session whole-body hyperthermia trial in major depressive disorder (Janssen and colleagues, JAMA Psychiatry, 2016) randomised 34 participants against a sham and reported a reduction in depression scores persisting for weeks. It is a striking result, it is 34 people, and it has not been replicated at scale. Small trials in fibromyalgia and inflammatory pain point in a similar direction with similar limitations.
Nobody has run a trial of hyperthermia with a lifespan or healthspan endpoint in humans. Anyone who tells you the heat resets your biological age is describing a hypothesis in the grammar of a result.
What is actually delivered here
The partner hospitals run whole-body immune hyperthermia as a monitored day-treatment session. What that means in practice on a retreat: the assessment comes first, and for this protocol the cardiovascular part of it is the gate — resting ECG, blood pressure, and a frank conversation about heart disease, arrhythmia, medication and hydration. A session runs in the day-treatment unit rather than a spa suite, with core temperature, heart rate and blood pressure monitored throughout and fluids managed. Afterwards you are tired, often pleasantly so, and the rest of the day is not scheduled.
The hospital can decline you, and for this protocol it declines people more often than for an infusion, because the exclusions are cardiovascular and common. That is the correct behaviour from a hospital, and a provider who never declines anyone for a heat protocol is not screening.
Why this is not cell therapy, and what that changes
Hyperthermia is a procedure, not a product. Nothing is manufactured, nothing is cultured, nothing is released against viability and sterility criteria, and nothing about it travels on the route that State Council Order No. 818 governs. Licensed cell and gene therapy in the zone is delivered for therapeutic purpose only — it proceeds where the assessment finds a treatable condition, or where you arrive holding a diagnosis or prescription from your own physician. The non-cell protocols carry no such restriction.
The trade is real and worth stating plainly. What you gain is access without a filed indication. What you lose is the scaffolding that the indication brings: no filed list defining who the protocol is for, no batch record, no release testing, no regulator having examined this specific use. The screen and the treating physician’s judgement are what is left, which is why the quality of the screen is the thing to interrogate.
The risks nobody’s brochure lists
Heat is a cardiovascular load, and the risk profile follows from that. Expect a raised heart rate and fluid shifts; hypotension, dehydration and electrolyte disturbance are the common adverse effects, and they are the reason the session is monitored rather than simply endured. Thermal injury — skin burns, applicator-interface burns, unintended heating of tissue in a radiofrequency field — is the hardware-specific risk, and it rises where sensation is impaired or metal is present. Extreme whole-body protocols add sedation risk, arrhythmia and, in rare reports, coagulation disturbance and organ strain; they are not what a retreat offers, and a provider blurring the two is a reason to leave.
Common exclusions: unstable or ischaemic heart disease, recent myocardial infarction or stroke, significant arrhythmia, uncontrolled hypertension, severe pulmonary or renal impairment, decompensated liver disease, pregnancy, seizure disorder, implanted electronic devices such as pacemakers, and metal implants within the treatment field. Impaired sensation — from neuropathy, for instance — matters, because the first warning of a burn is normally pain. Several common medications, diuretics and beta-blockers among them, change how you handle heat, and are a conversation before the first session rather than after it. The safety guide sets these alongside the risks of the cell and infusion programmes.
Who it suits, and who should not bother
It suits someone with a clean cardiovascular screen who understands what they are buying: a monitored physiological stress with a well-described short-term immune and inflammatory signature, a decent record as an oncology adjunct in hands that are not theirs, and no evidence at all of a longevity effect. It suits people who find the honest version interesting rather than disappointing.
It does not suit anyone with the exclusions above, and it does not suit anyone who has been sold it as an anti-ageing treatment — not because the protocol is bad but because the expectation is wrong, and a wrong expectation is the thing that makes a reasonable intervention feel like a swindle. If you are considering it as cancer treatment, the answer is not a retreat: regional hyperthermia belongs in an oncology plan, with your own oncologist, alongside the radiotherapy or chemotherapy the trials actually tested it with.
What it costs
We do not publish a price list for the treatment programmes. Hyperthermia is not one of the three regenerative programmes included in the four-day retreat, which is offered from about $2,700 all-in. Because it is session-based, what it costs tracks the number of sessions, the modality and the monitoring around them rather than a manufacturing batch — the structural difference from a cell course, which is set out in full in the programs and cost guide alongside the Alpine longevity clinics’ published $39,000–$115,000 range. Anything beyond the retreat’s inclusions is quoted in writing by the hospital that would deliver it, before you commit. A price given to you before anyone has looked at your heart is not a price for this protocol.
Seven questions to ask any hyperthermia clinic
Frequently asked
What is hyperthermia therapy?
Hyperthermia therapy is the controlled heating of the body, or of one region of it, to a temperature above normal — typically 39°C to 43°C — for a defined period under monitoring. It is not a sauna and not a hot bath: the heat is delivered by radiofrequency, microwave, infrared or capacitive applicators, the core or tissue temperature is measured rather than estimated, and the session is run to a target temperature for a target time. Three quite different things share the name. Local and regional hyperthermia heats a tumour or a body region and is used in oncology alongside radiotherapy or chemotherapy. Fever-range whole-body hyperthermia raises the whole core to roughly 38.5°C to 40°C and is used for immune and inflammatory effects. Extreme whole-body hyperthermia, at 41.8°C to 42°C, is an intensive-care-grade procedure with sedation and invasive monitoring, and is not a wellness treatment in any sense.
Is hyperthermia therapy available in China?
Yes. Regional and whole-body hyperthermia are in routine use in Chinese tertiary hospital oncology and rehabilitation departments, and whole-body immune hyperthermia is one of the session-based non-cell protocols offered by the partner hospitals in the Boao Lecheng pilot zone in Hainan. Because it is a procedure rather than a cell product, it carries no manufacturing run, no batch release testing and no filed-disease-indication restriction under State Council Order No. 818 — so it is available to well guests as part of a retreat as well as to patients. You are still screened first, and a cardiovascular assessment is part of that screen rather than a formality.
Does hyperthermia therapy work for cancer?
As an addition to radiotherapy or chemotherapy, in specific cancers, delivered by an oncology team with proper thermometry — the randomised evidence is real and it is decades old. The Dutch Deep Hyperthermia Trial (van der Zee and colleagues, Lancet 2000) reported that adding regional hyperthermia to radiotherapy in locally advanced cervical cancer raised complete response from about 57% to 83% and three-year survival from about 27% to 51%. A pooled analysis of five randomised trials in superficial recurrent breast cancer (Vernon and colleagues, 1996) reported complete response rising from roughly 41% to 59%. In high-risk soft-tissue sarcoma, adding regional hyperthermia to neoadjuvant chemotherapy improved local progression-free survival (Issels and colleagues, Lancet Oncology 2010) and, on long-term follow-up, overall survival (JAMA Oncology 2018). None of that is evidence that heat alone treats cancer, and none of it transfers to a wellness setting: it is adjunct therapy inside a cancer treatment plan, and it belongs to your oncologist.
Is whole-body hyperthermia the same as a sauna?
No, and the difference is the whole point. A sauna heats the air around you and your core temperature rises incidentally, by an amount nobody measures. Clinical whole-body hyperthermia heats you to a specified core temperature, verified continuously, and holds you there for a specified time while your heart rate, blood pressure, hydration and electrolytes are monitored. The dose is the temperature and the duration, and without measurement there is no dose. This matters when reading the evidence too: the well-known Finnish cohort finding that frequent sauna use is associated with lower cardiovascular mortality (Laukkanen and colleagues, JAMA Internal Medicine 2015) is an observational study about saunas, not a trial of clinical hyperthermia, and it cannot be used to support either one on the other's behalf.
What are the side effects and risks of hyperthermia therapy?
Heat is a cardiovascular load. The predictable effects are a raised heart rate, fluid shifts, hypotension, dehydration and electrolyte disturbance, and these are the reason the session is monitored rather than simply endured. Thermal injury — burns at the skin or at an applicator interface, and heating of tissue nobody intended to heat — is the risk specific to the delivery hardware, and is higher where sensation is impaired or metal is in the field. Extreme whole-body protocols add the risks of sedation and of a genuine physiological stress: arrhythmia, and in rare reports coagulation disturbance and organ strain. Common exclusions are unstable or ischaemic heart disease, significant arrhythmia, uncontrolled hypertension, severe pulmonary or renal impairment, pregnancy, seizure disorder, implanted electronic devices, and metal implants within a radiofrequency field. A provider who does not ask about your heart before quoting you a course is telling you something.
Do I need a diagnosis to have hyperthermia in the pilot zone?
No. Hyperthermia is not a cell product, so it does not travel on the route that State Council Order No. 818 governs. Licensed cell and gene therapy in the zone is currently delivered for therapeutic purpose only — it proceeds where the assessment finds a treatable condition, or where you arrive holding a diagnosis or prescription from your own physician. The non-cell protocols, hyperthermia among them, carry no such restriction. What you gain in access you lose in scaffolding: there is no filed indication list defining who it is for, and no release-tested batch behind it. The screen, and the hospital's willingness to decline you, is the safeguard that remains.
How much does hyperthermia therapy in China cost?
We do not publish a price list for the treatment programmes, and hyperthermia is not one of the three regenerative programmes included in the four-day retreat, which is offered from about $2,700 all-in. Because hyperthermia is session-based with no manufacturing run behind it, what it costs tracks the number of sessions, the modality and the monitoring around them rather than a batch — which is why a figure quoted before anyone has read your cardiovascular screen is telling you about the seller rather than the protocol. Anything beyond the retreat's own inclusions is quoted in writing by the hospital that would deliver it, before you commit.
Write to us →Tell us where you’re starting from — a care manager replies within one working day.Or download the Retreat Dossier (PDF) → — itinerary, inclusions, programs, practicalities.